Eris Lifesciences Limited announced the results of its postal ballot, conducted via remote e-voting, which concluded on December 24, 2025. Shareholders approved all four resolutions put forth. These included the re-appointment of Mr. Krishnakumar Vaidyanathan as Whole-Time Director and Ms. Kalpana Unadkat as Independent Director. Additionally, shareholders approved the issuance of up to 23,06,372 equity shares on a preferential basis for consideration other than cash. The fourth resolution, concerning material related party transactions with Mr. Naishadh Shah, was also passed. The remote e-voting period commenced on November 25, 2025, and concluded on December 24, 2025. The Scrutinizer, Mr. Ravi Kapoor, submitted his report on December 26, 2025. The resolutions were passed with a requisite majority, with strong favourable voting percentages across all items, including over 96% in favour for the director re-appointments and over 99% for the preferential issue and related party transactions. All resolutions were passed by the shareholders, indicating strong support for the company's proposed actions. The company has uploaded the e-voting results and the Scrutinizer's report on its website and the website of the service provider.